Sacituzumab or Chemo in First-Line TNBC: Which Is Better?

Pembrolizumab with sacituzumab govitecan instead of chemotherapy led to improved progression-free survival in PD-L1-postive locally advanced or metastatic triple-negative breast cancer.
Medscape Medical News

source https://www.medscape.com/viewarticle/sacituzumab-or-chemo-first-line-tnbc-which-better-2025a1000eqg?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost